ADVERTISEMENT
Press release content from PR Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from PR Newswire
Press release content from PR Newswire. The AP news staff was not involved in its creation.

Arranta Bio Announces Completion of Sale of Florida Site and Progress on $150M Investment Plan to Expand Development and Commercial Manufacturing Services

November 15, 2021 GMT
(PRNewsfoto/Arranta Bio)
(PRNewsfoto/Arranta Bio)
(PRNewsfoto/Arranta Bio)

WATERTOWN, Mass., Nov. 15, 2021 /PRNewswire/ -- Arranta Bio (“Arranta”), a leading contract development and manufacturing organization (CDMO) supporting advanced therapy pioneers, today announced the completion of the sale of its process development and GMP clinical manufacturing site in Gainesville, Florida, to Inceptor Bio and the transfer of client programs and key technical employees to Arranta’s Watertown, MA facility.

“We are delighted that Inceptor Bio will build on the foundation that we established in Gainesville and wish them every success in developing life-saving cell therapy products,” said Mark Bamforth, executive chair and CEO at Arranta, “and we are thrilled to continue to build and expand Arranta’s commercial-ready manufacturing team in Massachusetts, the global hub for biosciences.”

Arranta’s Watertown facility now has a team of over 160 employees focused on supporting microbiome clients, establishing messenger RNA vaccine capabilities, and manufacturing critical starting materials.

ADVERTISEMENT

Arranta has established a strong microbiome platform including proprietary media and cryopresevative formulations to maximize yields and enhance viability for live biopharmaceutical products that clients are testing in the clinic against a range of infectious, inflammatory, neurological, and oncology diseases.

In addition, Arranta is progressing the establishment of end-to-end mRNA capabilities that were announced recently and expects to begin laboratory-scale operations in January and to have starting materials, mRNA, lipid nanoparticle formulation, and a robotic sterile fill line installed in Watertown by the end of Q2 2022.

Arranta recently received permitting approval to progress the first build-out phase of laboratory and GMP capacity establishment at a second commercial-ready site in Boxborough, MA, which will be completed by mid-2022. “With over 200,000 ft2 of facilities in Watertown and Boxborough and over $150 million committed to building state-of-the-art facilities, Arranta has the capacity to respond to client needs for complex biopharmaceutical products that will change the lives of patients,” said David Stevens, President and COO at Arranta.

ADVERTISEMENT

About Arranta Bio
Founded in 2019, Arranta Bio is a visionary contract development and manufacturing organization (CDMO) that partners with companies seeking to develop and manufacture complex biological drugs and innovative therapies. Our dedicated team, state-of-the-art facilities, and unparalleled expertise are crucial for advancing products from development to commercial launch. Arranta Bio continues to expand capacity and development and manufacturing services across two sites with three distinct technology platforms designed to meet the evolving demands of our clients and partners. Additional information about Arranta Bio is available at www.arrantabio.com

Arranta Bio media contact:
Nathan Archibald
T: 321-271-0777
E: nathan.archibald@arrantabio.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/arranta-bio-announces-completion-of-sale-of-florida-site-and-progress-on-150m-investment-plan-to-expand-development-and-commercial-manufacturing-services-301424271.html

SOURCE Arranta Bio